Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosisJean‐Baptiste Gibier(Institut de Biologie de Lille), David Buob(Inserm)Modern PathologyOctober 20, 201710.1038/modpathol.2017.124Cited by 38SaveCiteExport RISWatch citationsRelated PapersDaratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population|British Journal of Haematology|2019|29Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France|Blood|2018|6